Evogene Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020 (Virtual Conference)
Evogene Ltd. (NASDAQ: EVGN) announced its participation in the H.C. Wainwright 22nd Annual Global Investment Conference from September 14-16, 2020. Ofer Haviv, President & CEO, will present a company overview on September 16 at 12:00 PM (EDT) and will be available for one-on-one meetings with institutional investors. Evogene leverages its Computational Predictive Biology (CPB) platform to enhance product discovery across multiple life-science sectors, including human health and agriculture. This participation underscores its commitment to engaging with investors.
- Participation in a prominent investment conference could increase visibility among investors.
- CEO Ofer Haviv will present the company's strategic vision, potentially attracting interest and investment.
- None.
REHOVOT, Israel, Sept. 9, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN.TA), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, today announced it will be featured as a presenting company at the H.C. Wainwright 22nd Annual Global Investment Conference. The conference is being held on September 14-16, 2020 virtually.
Mr. Ofer Haviv, President & CEO of Evogene, will provide an overview of the Company's business during a live presentation, scheduled for Wednesday, September 16, 12:00 PM (EDT), and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link (www.hcwevents.com ) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.
About Evogene Ltd.:
Evogene (NASDAQ: EVGN, TASE: EVGN.TA) is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules and genetic elements. Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd., medical cannabis through Canonic Ltd., ag-biologicals through Lavie Bio Ltd., ag-chemicals through AgPlenus Ltd., and ag-solutions for castor oil production through Casterra Ltd. For more information, please visit www.evogene.com
Forward Looking Statements:
This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the global spread of COVID-19, or the Coronavirus, the various restrictions deriving therefrom and those risk factors contained in Evogene's reports filed with the applicable securities authorities. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines (including as a result of the effect of the Coronavirus), Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Evogene Investor Contact: | US Investor Relations: |
Rivka Neufeld Investor Relations and Public Relations Manager T: +972-8-931-1940 | Joseph Green |
Laine Yonker Edison Group T: +1 646-653-7035 |
View original content:http://www.prnewswire.com/news-releases/evogene-announces-participation-at-the-hc-wainwright-22nd-annual-global-investment-conference-on-september-14-16-2020-virtual-conference-301126266.html
SOURCE Evogene
FAQ
What is Evogene Ltd.'s stock symbol?
When is Evogene's presentation at the H.C. Wainwright conference?
What industries does Evogene focus on?
How can investors participate in the conference?
